Sermorelin before and after: what to expect and when. | Reddit

Why does sermorelin take so long to produce results?

To understand why sermorelin takes time to produce noticeable changes, it helps to understand what it actually does. Sermorelin is a 29-amino-acid analogue of growth hormone-releasing hormone (GHRH), the hypothalamic peptide that signals the anterior pituitary to secrete GH.

When administered subcutaneously, sermorelin prompts a pulse of GH release from the pituitary. Over repeated doses—typically administered at bedtime to coincide with the body’s natural nocturnal GH peak—the amplitude and frequency of GH pulses gradually increases. This, in turn, raises IGF-1 (insulin-like growth factor 1) levels in the liver and peripheral tissues, since IGF-1 is produced in response to GH signaling.

IGF-1 is the primary mediator of many of the downstream effects associated with GH optimization: protein synthesis, fat metabolism, collagen production, and cellular repair processes. Because IGF-1 levels build incrementally, the clinically observable effects accumulate over weeks to months rather than appearing acutely after the first dose.

Sermorelin results timeline at a glance

Patient-reported observations from supervised protocols. Not guaranteed outcomes for any individual.

What happens in weeks 1–4 on sermorelin?

The first month on a sermorelin protocol is typically when patients notice the most subjective changes, even though measurable biomarker shifts are still modest at this stage.

• Sleep quality: The most commonly reported early change is improved sleep. GH secretion is concentrated in the early stages of deep (slow-wave) sleep, and the bedtime dosing protocol takes advantage of this. Many patients report deeper, more restorative sleep within the first two to four weeks.
• Energy and morning alertness: Improved sleep depth often translates to better morning energy levels. Some patients notice this as one of the earliest recognizable changes.
• Injection site familiarity: The practical experience of the protocol, technique, timing, and any local reactions, is typically sorted out in the first few weeks.

What is not happening yet: significant changes in body composition, lean mass, or recovery speed. IGF-1 levels have not had enough time to build meaningfully.

What changes between weeks 4 and 8 as the GH axis builds?

Through the second month, IGF-1 continues to rise toward a clinically meaningful range. Patients often report:

• Recovery speed: Faster recovery from exercise and physical activity is frequently mentioned at this stage. This likely reflects increasing protein synthesis and cellular repair signaling driven by rising IGF-1.
• Mood and motivation: Some patients notice improvements in mood consistency and motivation, though this is highly variable and difficult to attribute solely to the peptide protocol.
• Skin hydration: GH stimulates collagen synthesis. Early changes in skin texture and hydration are sometimes noted by month two, though more pronounced effects come later.

Months 2–4: when body composition shifts become visible

This is typically when patients on a consistent protocol begin to see body composition changes that are meaningful to them—provided they are maintaining appropriate nutrition and physical activity. GH and IGF-1 support lean mass retention and fat metabolism, but they do not operate independently of diet and training.

• Lean mass: Patients often report that their ability to add or maintain lean muscle mass improves. This reflects the protein-synthesis promoting effects of elevated IGF-1.
• Fat distribution: GH has lipolytic effects, particularly on visceral fat. Some patients notice changes in body composition, especially midsection fat, that become more apparent in this phase.
• Lab trends: A supervising clinician typically orders labs around the 3-month mark to assess IGF-1 levels and guide dose adjustments if needed.

Months 4–6: full protocol effects

By the fifth and sixth months of a consistent sermorelin protocol with appropriate clinical monitoring, the GH axis has typically reached a new, higher output equilibrium. Changes that patients commonly report at this stage include:

• Sustained body composition improvement: Lean mass gains and fat reduction that started in months two through four continue to compound with consistent adherence.
• Joint comfort: GH and IGF-1 support collagen matrix synthesis in connective tissue. Some patients report improved joint comfort over extended protocols, though this is not a guaranteed outcome.
• Hair and skin quality: Longer-term effects on skin thickness, collagen density, and hair growth are sometimes reported at this stage.

Clinical monitoring throughout the protocol allows the prescribing clinician to assess response objectively via labs, adjust dosing, and identify any adverse trends before they become problems.

Before and after in the trials: what was measured

The table above is what patients report. The published trials of GHRH(1-29), the molecule sermorelin is, measured the before and the after in bloodwork and body composition, in older adults with low GH output for their age. Three of them are worth knowing.

• 14 days, twice daily, ten men around 68: GHRH(1-29) at 1 mg twice daily raised 24-hour GH, peak amplitude and IGF-1 significantly, to levels no longer different from men in their twenties, with no change in fasting glucose, blood pressure or blood chemistry. The 0.5 mg dose did less.
• 6 weeks, nightly, eleven men 64 to 76: 2 mg at bedtime raised nocturnal GH release and peak amplitude but did not move IGF-1, and two of six strength measures improved while DEXA body composition, weight, glucose and lipids did not change. The authors concluded single nightly doses were less effective than multiple daily doses at moving IGF-1.
• 16 weeks, nightly, nineteen adults 55 to 71: a GHRH analog at 10 micrograms per kilogram raised nocturnal GH in both sexes, with IGF-1 and IGFBP-3 up within two weeks and drifting back toward baseline by week 16; skin thickness rose in both sexes; lean mass, insulin sensitivity, general well-being and libido rose in men only; sleep quality was unchanged in both, and blood pressure and weight did not move.

Read those against the timeline above and two things stand out. The bloodwork moves within two weeks, well before anything is visible, which is why a clinician orders IGF-1 labs rather than waiting for the mirror. And the one trial that asked about sleep by questionnaire found no change, so the early sleep improvement patients describe is a report, not a trial result. None of these studies used photographs as an endpoint; a before-and-after picture with no baseline labs, dose or timeline cannot be checked against anything.

Why do individual sermorelin results vary so much?

The variation in sermorelin results across patients is substantial. Several factors determine how pronounced the response will be:

• Baseline GH status: Patients who have more significant age-related GH decline tend to have more room for noticeable improvement. Those with already-normal GH secretion may see more modest changes.
• Age: GH secretion declines with age. Younger patients with relatively intact pituitary function may respond differently than older patients.
• Diet and training: GH and IGF-1 are anabolic signals that work in the context of a nutritional and physical environment. Protocol benefits are substantially attenuated by poor sleep hygiene, inadequate protein intake, or sedentary behavior.
• Protocol adherence: Sermorelin has a short half-life. Inconsistent dosing disrupts the cumulative effect on GH pulse amplitude. Consistent bedtime dosing is important for response.
• Pituitary reserve: Sermorelin works by stimulating the pituitary, not bypassing it. Patients with compromised pituitary function may have limited response. A clinician evaluation before starting the protocol is essential.

Frequently asked questions